

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Levamisole / Oxyclozanide Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 9374284-00006      Date of last issue: 04.04.2023  
Date of first issue: 27.08.2021

---

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Levamisole / Oxyclozanide Formulation

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-stance/Mixture : Veterinary product

Recommended restrictions on use : Not applicable

#### 1.3 Details of the supplier of the safety data sheet

Company : MSD  
Walton Manor, Walton  
MK7 7AJ Milton Keynes - United Kingdom

Telephone : +1-908-740-4000

E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

#### 1.4 Emergency telephone number

+1-908-423-6000

---

### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

**Classification (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)**

Reproductive toxicity, Category 2      H361d: Suspected of damaging the unborn child.  
Long-term (chronic) aquatic hazard, Category 2      H411: Toxic to aquatic life with long lasting effects.

#### 2.2 Label elements

**Labelling (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)**

Hazard pictograms :

Signal word : Warning

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Levamisole / Oxyclozanide Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 9374284-00006      Date of last issue: 04.04.2023  
Date of first issue: 27.08.2021

Hazard statements : H361d Suspected of damaging the unborn child.  
H411 Toxic to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**  
P201 Obtain special instructions before use.  
P273 Avoid release to the environment.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.  
**Response:**  
P308 + P313 IF exposed or concerned: Get medical advice/ attention.  
P391 Collect spillage.  
**Storage:**  
P405 Store locked up.

Hazardous components which must be listed on the label:  
oxyclozanide

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

## SECTION 3: Composition/information on ingredients

### 3.2 Mixtures

#### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
oxyclozanide	2277-92-1 218-904-0	Repr. 2; H361d STOT SE 2; H371 (Central nervous system) STOT RE 2; H373 (Brain, Liver) Aquatic Acute 1; H400 Aquatic Chronic 1; H410  M-Factor (Acute aquatic toxicity): 1 M-Factor (Chronic aquatic toxicity): 1	>= 3 - < 10
levamisole hydrochloride	16595-80-5 240-654-6	Acute Tox. 3; H301 Repr. 2; H361d	>= 1 - < 2.5

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Levamisole / Oxyclozanide Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 9374284-00006      Date of last issue: 04.04.2023  
Date of first issue: 27.08.2021

		STOT RE 2; H373 (Blood, Testis) Aquatic Chronic 3; H412	
Citric acid	77-92-9 201-069-1 607-750-00-3	Eye Irrit. 2; H319 STOT SE 3; H335	>= 1 - < 10
Substances with a workplace exposure limit :			
Kaolin	1332-58-7 310-194-1		>= 1 - < 10

For explanation of abbreviations see section 16.

### SECTION 4: First aid measures

#### 4.1 Description of first aid measures

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : Flush eyes with water as a precaution.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.  
Never give anything by mouth to an unconscious person.

#### 4.2 Most important symptoms and effects, both acute and delayed

- Risks : Suspected of damaging the unborn child.

#### 4.3 Indication of any immediate medical attention and special treatment needed

- Treatment : Treat symptomatically and supportively.

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Levamisole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	9374284-00006	Date of first issue: 27.08.2021

### SECTION 5: Firefighting measures

#### 5.1 Extinguishing media

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

#### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides  
Silicon oxides  
Metal oxides  
Chlorine compounds  
Nitrogen oxides (NO<sub>x</sub>)

#### 5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

### SECTION 6: Accidental release measures

#### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

#### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g. by containment or oil barriers).  
Retain and dispose of contaminated wash water.  
If spillage enters rivers or watercourses, inform the Environment Agency (emergency telephone number 0800 807060).

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Levamisole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	9374284-00006	Date of first issue: 27.08.2021

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.  
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

## SECTION 7: Handling and storage

### 7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe mist or vapours.  
Do not swallow.  
Avoid contact with eyes.  
Avoid prolonged or repeated contact with skin.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Do not eat, drink or smoke when using this product.  
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

### 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers : Keep in properly labelled containers. Store locked up. Store in accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:  
Strong oxidizing agents  
Gases

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Levamisole / Oxyclozanide Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 9374284-00006      Date of last issue: 04.04.2023  
Date of first issue: 27.08.2021

### 7.3 Specific end use(s)

Specific use(s) : No data available

## SECTION 8: Exposure controls/personal protection

### 8.1 Control parameters

#### Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Kaolin	1332-58-7	TWA (Respirable dust)	2 mg/m <sup>3</sup>	GB EH40
oxyclozanide	2277-92-1	TWA	0.4 mg/m <sup>3</sup> (OEB 2)	Internal
levamisole hydrochloride	16595-80-5	TWA	20 µg/m <sup>3</sup> (OEB 3)	Internal
	Further information: Skin			
		Wipe limit	200 µg/100 cm <sup>2</sup>	Internal

#### Predicted No Effect Concentration (PNEC):

Substance name	Environmental Compartment	Value
Citric acid	Fresh water	0.44 mg/l
	Marine water	0.044 mg/l
	Sewage treatment plant	1000 mg/l
	Fresh water sediment	34.6 mg/kg dry weight (d.w.)
	Marine sediment	3.46 mg/kg dry weight (d.w.)
	Soil	33.1 mg/kg dry weight (d.w.)

### 8.2 Exposure controls

#### Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

#### Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Levamisole / Oxyclozanide Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 9374284-00006      Date of last issue: 04.04.2023  
Date of first issue: 27.08.2021

---

Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Equipment should conform to BS EN 143
Filter type	:	Particulates type (P)

---

### SECTION 9: Physical and chemical properties

#### 9.1 Information on basic physical and chemical properties

Appearance	:	liquid
Colour	:	No data available
Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Levamisole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	9374284-00006	Date of first issue: 27.08.2021

---

Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

### 9.2 Other information

Flammability (liquids)	:	No data available
Molecular weight	:	No data available
Particle size	:	Not applicable

---

## SECTION 10: Stability and reactivity

### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions	:	Can react with strong oxidizing agents.
---------------------	---	---

### 10.4 Conditions to avoid

Conditions to avoid	:	None known.
---------------------	---	-------------

### 10.5 Incompatible materials

Materials to avoid	:	Oxidizing agents
--------------------	---	------------------

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

---

## SECTION 11: Toxicological information

### 11.1 Information on toxicological effects

Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact
--	---	--



# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Levamisole / Oxyclozanide Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 9374284-00006      Date of last issue: 04.04.2023  
Date of first issue: 27.08.2021

---

### Acute toxicity

Not classified based on available information.

### Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg  
Method: Calculation method

### Components:

#### **oxyclozanide:**

Acute oral toxicity : LD50 (Rat): 3,519 mg/kg  
Target Organs: Central nervous system

Acute toxicity (other routes of administration) : LDLo (sheep): 10 mg/kg  
Application Route: Intravenous

#### **levamisole hydrochloride:**

Acute oral toxicity : LD50 (Rat): 180 mg/kg  
LD50 (Mouse): 223 mg/kg  
LD50 (Rabbit): 458 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

#### **Citric acid:**

Acute oral toxicity : LD50 (Mouse): 5,400 mg/kg

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 402  
Assessment: The substance or mixture has no acute dermal toxicity

#### **Kaolin:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
Remarks: Based on data from similar materials

Acute inhalation toxicity : LC50 (Rat): > 2.07 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Assessment: The substance or mixture has no acute inhalation toxicity  
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rat): > 5,000 mg/kg  
Assessment: The substance or mixture has no acute dermal toxicity  
Remarks: Based on data from similar materials

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Levamisole / Oxyclozanide Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 9374284-00006      Date of last issue: 04.04.2023  
Date of first issue: 27.08.2021

---

### **Skin corrosion/irritation**

Not classified based on available information.

#### **Components:**

##### **oxyclozanide:**

Remarks : Not classified due to lack of data.

##### **levamisole hydrochloride:**

Remarks : No data available

##### **Citric acid:**

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : No skin irritation

##### **Kaolin:**

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : No skin irritation  
Remarks : Based on data from similar materials

### **Serious eye damage/eye irritation**

Not classified based on available information.

#### **Components:**

##### **oxyclozanide:**

Remarks : Not classified due to lack of data.

##### **levamisole hydrochloride:**

Remarks : No data available

##### **Citric acid:**

Species : Rabbit  
Method : OECD Test Guideline 405  
Result : Irritation to eyes, reversing within 21 days

##### **Kaolin:**

Species : Rabbit  
Result : No eye irritation  
Remarks : Based on data from similar materials

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Levamisole / Oxyclozanide Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 9374284-00006      Date of last issue: 04.04.2023  
Date of first issue: 27.08.2021

---

### Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

#### Respiratory sensitisation

Not classified based on available information.

#### Components:

##### oxyclozanide:

Exposure routes : Dermal  
Remarks : Not classified due to lack of data.

##### levamisole hydrochloride:

Remarks : No data available

### Germ cell mutagenicity

Not classified based on available information.

#### Components:

##### oxyclozanide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Chromosomal aberration  
Test system: Human lymphocytes  
Result: positive

Test Type: Mouse Lymphoma  
Result: positive

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Application Route: Oral  
Result: negative

Test Type: unscheduled DNA synthesis assay  
Species: Rat  
Cell type: Liver cells  
Application Route: Oral  
Result: negative

Germ cell mutagenicity- Assessment : Weight of evidence does not support classification as a germ cell mutagen.

##### levamisole hydrochloride:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Chromosome aberration test in vitro

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Levamisole / Oxyclozanide Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 9374284-00006      Date of last issue: 04.04.2023  
Date of first issue: 27.08.2021

---

Result: negative

### Citric acid:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: in vitro micronucleus test  
Result: positive

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow  
cytogenetic test, chromosomal analysis)  
Species: Rat  
Application Route: Ingestion  
Result: negative

### Carcinogenicity

Not classified based on available information.

### Components:

#### oxyclozanide:

Remarks : Not classified due to lack of data.

#### levamisole hydrochloride:

Species : Mouse  
Application Route : Oral  
Exposure time : 2 Years  
NOAEL : 80 mg/kg body weight  
Remarks : No significant adverse effects were reported

Species : Rat  
Application Route : Oral  
Exposure time : 2 Years  
NOAEL : 40 mg/kg body weight  
Remarks : No significant adverse effects were reported

### Reproductive toxicity

Suspected of damaging the unborn child.

### Components:

#### oxyclozanide:

Effects on fertility : Test Type: Two-generation reproduction toxicity study  
Species: Rat, male and female  
Application Route: Oral  
General Toxicity - Parent: NOAEL: 25 - 35 mg/kg body weight  
Symptoms: Reduced body weight, No effects on embryofetal  
and postnatal development

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Levamisole / Oxyclozanide Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 9374284-00006      Date of last issue: 04.04.2023  
Date of first issue: 27.08.2021

---

Result: No effects on fertility

Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Oral

General Toxicity - Parent: LOAEL: 75 - 100 mg/kg body weight

Symptoms: Reduced body weight, No effects on embryofoetal and postnatal development

Result: No effects on fertility

Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Oral

Early Embryonic Development: LOAEL: 75 - 100 mg/kg body weight

Result: No fetotoxicity, No teratogenic effects

Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Oral

General Toxicity - Parent: LOAEL: 80 - 160 mg/kg body weight

Result: No fetotoxicity, No teratogenic effects, No effects on fertility

Effects on foetal development

: Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: NOAEL: 200 mg/kg body weight

Result: No fetotoxicity, No teratogenic effects

Test Type: Development

Species: Rat

Application Route: Oral

General Toxicity Maternal: LOAEL: 100 mg/kg body weight

Result: No fetotoxicity, No teratogenic effects

Test Type: Development

Species: Rabbit

Application Route: Oral

Developmental Toxicity: NOAEL: 32 mg/kg body weight

Result: Fetotoxicity, Skeletal malformations

Reproductive toxicity - Assessment

: Suspected of damaging the unborn child.

### levamisole hydrochloride:

Effects on fertility

: Test Type: Three-generation reproduction toxicity study

Species: Rat

Application Route: Oral

Result: No significant adverse effects were reported

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Levamisole / Oxyclozanide Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 9374284-00006      Date of last issue: 04.04.2023  
Date of first issue: 27.08.2021

---

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: 20 mg/kg body weight  
Result: Fetotoxicity

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: LOAEL: 40 mg/kg body weight  
Result: Fetotoxicity

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

### Citric acid:

Effects on foetal development : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

### STOT - single exposure

Not classified based on available information.

#### Components:

##### oxyclozanide:

Exposure routes : Oral  
Target Organs : Central nervous system  
Assessment : May cause damage to organs.

##### Citric acid:

Assessment : May cause respiratory irritation.

### STOT - repeated exposure

Not classified based on available information.

#### Components:

##### oxyclozanide:

Target Organs : Brain, Liver  
Assessment : May cause damage to organs through prolonged or repeated exposure.

##### levamisole hydrochloride:

Target Organs : Blood, Testis  
Assessment : May cause damage to organs through prolonged or repeated exposure.

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Levamisole / Oxyclozanide Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 9374284-00006      Date of last issue: 04.04.2023  
Date of first issue: 27.08.2021

---

### Repeated dose toxicity

#### Components:

##### **oxyclozanide:**

Species : Rat  
NOAEL : 9 mg/kg  
LOAEL : 44.5 mg/kg  
Application Route : Oral  
Exposure time : 3 Months  
Target Organs : Brain, Liver, spleen, Adrenal gland  
Symptoms : Liver effects

Species : Dog  
NOAEL : 5 mg/kg  
LOAEL : 25 mg/kg  
Application Route : Oral  
Exposure time : 3 Months  
Target Organs : Brain, Liver  
Symptoms : blood effects, alteration in liver enzymes

##### **levamisole hydrochloride:**

Species : Rat  
NOAEL : 2.5 mg/kg  
Application Route : Oral  
Exposure time : 18 Months  
Target Organs : Testis

Species : Dog  
LOAEL : 20 mg/kg  
Application Route : Oral  
Exposure time : 18 Months  
Target Organs : Blood

Species : Dog  
LOAEL : 40 mg/kg  
Application Route : Oral  
Exposure time : 3 Months

##### **Citric acid:**

Species : Rat  
NOAEL : 4,000 mg/kg  
LOAEL : 8,000 mg/kg  
Application Route : Ingestion  
Exposure time : 10 Days

### Aspiration toxicity

Not classified based on available information.

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Levamisole / Oxyclozanide Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 9374284-00006      Date of last issue: 04.04.2023  
Date of first issue: 27.08.2021

---

### Components:

#### **oxyclozanide:**

Not applicable

### **Experience with human exposure**

### Components:

#### **oxyclozanide:**

Ingestion : Symptoms: May cause, Gastrointestinal disturbance, Central nervous system depression

#### **levamisole hydrochloride:**

Ingestion : Symptoms: Nausea, Vomiting, Headache, Dizziness, hypotension

---

## SECTION 12: Ecological information

### 12.1 Toxicity

### Components:

#### **oxyclozanide:**

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.69 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202

M-Factor (Acute aquatic toxicity) : 1

M-Factor (Chronic aquatic toxicity) : 1

#### **levamisole hydrochloride:**

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): 37.3 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 64 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202

#### **Citric acid:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 1,535 mg/l  
Exposure time: 24 h

#### **Kaolin:**



# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Levamisole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	9374284-00006	Date of first issue: 27.08.2021

---

Toxicity to fish (Chronic toxicity) : NOELR: > 100 mg/l  
Exposure time: 30 d  
Species: Oncorhynchus mykiss (rainbow trout)

### 12.2 Persistence and degradability

#### Components:

##### **oxyclozanide:**

Stability in water : Hydrolysis: 50 %(156 d)  
Method: OECD Test Guideline 111

##### **Citric acid:**

Biodegradability : Result: Readily biodegradable.  
Biodegradation: 97 %  
Exposure time: 28 d  
Method: OECD Test Guideline 301B

### 12.3 Bioaccumulative potential

#### Components:

##### **oxyclozanide:**

Partition coefficient: n-octanol/water : log Pow: 3.99  
pH: 7  
Method: OECD Test Guideline 107

##### **Citric acid:**

Partition coefficient: n-octanol/water : log Pow: -1.72

### 12.4 Mobility in soil

#### Components:

##### **oxyclozanide:**

Distribution among environmental compartments : log Koc: 4.83  
Method: OECD Test Guideline 106

### 12.5 Results of PBT and vPvB assessment

#### Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

### 12.6 Endocrine disrupting properties

#### Product:

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Levamisole / Oxyclozanide Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 9374284-00006      Date of last issue: 04.04.2023  
Date of first issue: 27.08.2021

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### 12.7 Other adverse effects

No data available

## SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

## SECTION 14: Transport information

### 14.1 UN number

ADN : UN 3082  
ADR : UN 3082  
RID : UN 3082  
IMDG : UN 3082  
IATA : UN 3082

### 14.2 UN proper shipping name

ADN : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (oxyclozanide)  
ADR : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (oxyclozanide)  
RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (oxyclozanide)  
IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (oxyclozanide)  
IATA : Environmentally hazardous substance, liquid, n.o.s.

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Levamisole / Oxyclozanide Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 9374284-00006      Date of last issue: 04.04.2023  
Date of first issue: 27.08.2021

(oxyclozanide)

### 14.3 Transport hazard class(es)

	Class	Subsidiary risks
<b>ADN</b>	: 9	
<b>ADR</b>	: 9	
<b>RID</b>	: 9	
<b>IMDG</b>	: 9	
<b>IATA</b>	: 9	

### 14.4 Packing group

<b>ADN</b>	
Packing group	: III
Classification Code	: M6
Hazard Identification Number	: 90
Labels	: 9
<b>ADR</b>	
Packing group	: III
Classification Code	: M6
Hazard Identification Number	: 90
Labels	: 9
Tunnel restriction code	: (-)
<b>RID</b>	
Packing group	: III
Classification Code	: M6
Hazard Identification Number	: 90
Labels	: 9
<b>IMDG</b>	
Packing group	: III
Labels	: 9
EmS Code	: F-A, S-F
<b>IATA (Cargo)</b>	
Packing instruction (cargo aircraft)	: 964
Packing instruction (LQ)	: Y964
Packing group	: III
Labels	: Miscellaneous
<b>IATA (Passenger)</b>	
Packing instruction (passenger aircraft)	: 964
Packing instruction (LQ)	: Y964
Packing group	: III
Labels	: Miscellaneous

### 14.5 Environmental hazards

<b>ADN</b>	
Environmentally hazardous	: yes

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Levamisole / Oxyclozanide Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 9374284-00006      Date of last issue: 04.04.2023  
Date of first issue: 27.08.2021

---

### ADR

Environmentally hazardous : yes

### RID

Environmentally hazardous : yes

### IMDG

Marine pollutant : yes

### IATA (Passenger)

Environmentally hazardous : yes

### IATA (Cargo)

Environmentally hazardous : yes

### 14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

### 14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

---

## SECTION 15: Regulatory information

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Relevant EU provisions transposed through retained EU law

UK REACH List of restrictions (Annex 17)	: Conditions of restriction for the following entries should be considered: Number on list 3
	Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not.
UK REACH Candidate list of substances of very high concern (SVHC) for Authorisation	: Not applicable
The Persistent Organic Pollutants Regulations (retained Regulation (EU) 2019/1021 as amended for Great Britain)	: Not applicable
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer	: Not applicable
UK REACH List of substances subject to authorisation (Annex XIV)	: Not applicable
GB Export and import of hazardous chemicals - Prior Informed Consent (PIC) Regulation	: Not applicable

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Levamisole / Oxyclozanide Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 9374284-00006      Date of last issue: 04.04.2023  
Date of first issue: 27.08.2021

Control of Major Accident Hazards Regulations 2015 (COMAH)

		Quantity 1	Quantity 2
E2	ENVIRONMENTAL HAZARDS	200 t	500 t

### Other regulations:

Take note of The Management of Health and Safety at Work Regulations 1999 (requirements relating to new and expectant mothers at work contained in Regulation 16 to 18) and of the Pregnant Workers Directive 92/85/EEC.

### The components of this product are reported in the following inventories:

AICS : not determined  
DSL : not determined  
IECSC : not determined

### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

## SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

### Full text of H-Statements

H301 : Toxic if swallowed.  
H319 : Causes serious eye irritation.  
H335 : May cause respiratory irritation.  
H361d : Suspected of damaging the unborn child.  
H371 : May cause damage to organs if swallowed.  
H373 : May cause damage to organs through prolonged or repeated exposure.  
H373 : May cause damage to organs through prolonged or repeated exposure if swallowed.  
H400 : Very toxic to aquatic life.  
H410 : Very toxic to aquatic life with long lasting effects.  
H412 : Harmful to aquatic life with long lasting effects.

### Full text of other abbreviations

Acute Tox. : Acute toxicity  
Aquatic Acute : Short-term (acute) aquatic hazard  
Aquatic Chronic : Long-term (chronic) aquatic hazard  
Eye Irrit. : Eye irritation  
Repr. : Reproductive toxicity  
STOT RE : Specific target organ toxicity - repeated exposure  
STOT SE : Specific target organ toxicity - single exposure  
GB EH40 : UK. EH40 WEL - Workplace Exposure Limits  
GB EH40 / TWA : Long-term exposure limit (8-hour TWA reference period)

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Levamisole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	9374284-00006	Date of first issue: 27.08.2021

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

### Classification of the mixture:

Repr. 2	H361d
Aquatic Chronic 2	H411

### Classification procedure:

Calculation method
Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Levamisole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	9374284-00006	Date of first issue: 27.08.2021

---

intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

GB / EN